Guggenheim Maintains Neutral on Amgen, Raises Price Target to $347

Amgen Inc. +0.34% Post

Amgen Inc.

AMGN

349.39

349.39

+0.34%

0.00% Post
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ: AMGN) with a Neutral and raises the price target from $305 to $347.